1219332-91-8
1219332-91-8
Chemical Structure
rac-Lenalidomide-13C5
Synonym(s): CC-5013-13C5
- CAS No.: 1219332-91-8
- Formula:C813C5H13N3O3
- Molecular Weight:264.22
InChIKey: GOTYRUGSSMKFNF-GSUYAWNGSA-N
SMILES: O=[13C](N1)[13CH2][13CH2][13CH](N2CC3=C(C=CC=C3C2=O)N)[13C]1=O
Biological Activity: rac Lenalidomide-13C5 is a 13C-labeled rac Lenalidomide[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
rac-Lenalidomide-13C5 | rac Lenalidomide-13C5 is a 13C-labeled rac Lenalidomide. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lenalidomide (Standard) | 99.98% | Lenalidomide (Standard) is the analytical standard of Lenalidomide. This product is intended for research and analytical applications. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lenalidomide-13C5,15N | Lenalidomide-13C5,15N is 15N and 13C labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lenalidomide-d5 | 99.32% | Lenalidomide-d5 is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lenalidomide-d4 | Lenalidomide-d4 (CC-5013-d4) is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lenalidomide | 99.94% | Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
